Immuno-oncology
Feature
Outpatient CAR T: Safe, Effective, Accessible
'The future of CAR T-cell therapy lies in balancing safety with accessibility,' says expert.
From the Journals
Risk Assessment Tool Can Help Predict Fractures in Cancer
Researchers collected data on bone mineral density and fractures in 9,877 patients with cancer and 45,875 matched control individuals without...
Feature
Many Hurdles Exist to Treating Lung Cancer With CAR T Cells
Unleashing the immune system in a highly specific manner, ‘is obviously, in a way, a holy grail’ in lung cancer, said an expert at the W...
Conference Coverage
A Simple Blood Test May Predict Cancer Risk in T2D
Can the markers of inflammation IL-6, tumor necrosis factor alpha (TNF-alpha), and high-sensitivity C-reactive protein (hsCRP) be predictive...
Commentary
Cancer Treatment 101: A Primer for Non-Oncologists
Doctor explains why he thinks time of diagnosis is the best time for molecular testing of a new malignant tumor.
Latest News
Diagnosing, Treating Rashes In Patients on Immune Checkpoint Inhibitors
Cutaneous immune-related adverse events are the most frequently reported and most visible adverse effects of checkpoint inhibition.
Feature
Jeffrey Weber, MD, PhD, Giant of Cancer Care, Dies
He was a principal investigator on many studies, including pivotal clinical drug trials in melanoma.
From the Journals
Immunotherapy and Survival in Advanced NSCLC: Does Obesity Matter?
Researchers evaluated 31,257 patients with advanced NSCLC from Japan who received immune checkpoint inhibitors or conventional chemotherapy.
News from the FDA/CDC
FDA Approves Lymphir for R/R Cutaneous T-Cell Lymphoma
The immunotherapy is a reformulation of denileukin diftitox that was initially approved for certain patients with persistent or recurrent...
Feature
Immunotherapy May Be Overused in Dying Patients With Cancer
“There are patients who are getting immunotherapy who shouldn’t,” according to a surgical oncologist from Yale.
From the Journals
Modest Gains Shown in Breast Cancer Immunotherapy Trials
Researchers evaluated 331 immunotherapy trials, enrolling nearly 50,000 patients with breast cancer.